Effects of adding tocotrienol-tocopherol mixed fraction and vitamin C supplementation on coronary risk biomarkers in patients with hypercholesterolaemia with moderate coronary risk
| Autor: | Tengku Saifudin Tengku Ismail, Huzaimi Haron, Muhamed T. Osman, Hapizah Md Nawawi, Suhaila Abd Muid, A. A. A. Razak, Sushil Kumar R Vasudevan, Thuhairah Hasrah Abdul Rahman, Anis Safura Ramli |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Statin Vitamin C medicine.drug_class business.industry Atorvastatin Medicine (miscellaneous) Inflammation Clinical trial 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology Endocrinology chemistry Coronary risk Internal medicine medicine Pharmacology (medical) Tocotrienol Tocopherol General Pharmacology Toxicology and Pharmaceutics medicine.symptom business medicine.drug |
| Zdroj: | Journal of Applied Pharmaceutical Science. :133-138 |
| ISSN: | 2231-3354 |
| DOI: | 10.7324/japs.2016.60418 |
| Popis: | Article history: Received on: 07/01/2016 Revised on: 07/02/2016 Accepted on: 24/03/2016 Available online: 30/04/2016 This study was a prospective clinical trial to investigate the effects of adding combined tocotrienol-tocopherol mixed fraction (TTMF) and vitamin C (TTMF+C) supplementation on coronary biomarkers in non-statin and statin treated patients with hypercholesterolaemia (HC) with moderate coronary risk. A total of 35 patients were randomised at baseline into one of two groups, (G1) TTMF+C (320mg TTMF plus 500mg vitamin C) alone daily and (G2) TTMF+C (320mg TTMF plus 500mg vitamin C) plus atorvastatin 10 mg daily. The entire supplementation were taken for 12 months. Fasting serum samples were taken at baseline, 2weeks, 3months, 6months and 12months post-randomisation and analysed for inflammatory biomarkers; high sensitivity Creactive protein (hsCRP) and interleukin-6 (IL6). Combination of TTMF and vitamin C supplementation leads to neutral effects on lipid profiles and inflammation; with no added benefit in statin-treated HC patients with moderate coronary risk. This neutral effects may be attributed to the tocopherol composition in TTMF which could possibly attenuate any potential beneficial effects of tocotrienols. Clinical studies using pure tocotrienols in the absence of tocopherols would further confirm this. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|